On September 27, CARGENE BIOPHARMA officially announced its renaming to "CARGENE BIOPHARMA." This change reflects the company's unwavering commitment to achieving groundbreaking innovations in drug development by fully leveraging RNA technology and breakthrough biological insights in the field of liver regeneration.The name "CARGENE" originates from a legendary lake in ancient Greek mythology, renowned for its exceptional healing properties.CARGENE BIOPHARMA CEO Ms. He Qizhi stated:"The company renamed itself to 'CARGENE BIOPHARMA,' representing our redefinition of..."Ambitious Goals for Liver Disease Treatment and Other Disease Treatments.This name symbolizes healing, innovation, and purpose.CARGENE BIOPHARMA is not justIt is a name that also reflects our vision for the future andThe Core Mission of the Company:"Through the most advanced biopharmaceutical solutions, to cure diseases and improve lives."We are passionate about this new chapter of the company and look forward to sharing this hopeful journey with you. The combination of regenerative science and RNA technology will revolutionize the pharmaceutical landscape and create an entirely new future.About CARGENE BIOPHARMACARGENE BIOPHARMA is a small nucleic acid drug research and development company that focuses on fully leveraging the liver's inherent regenerative potential to provide innovative solutions for patients with limited treatment options. Our innovation originates from Dr. Torsten Wuestefeld's Quartz.TMTarget Identification Platform, a multifunctional in vivo functional genomics screening platform that generates a series of potential targets for liver diseases and other conditions. Our lead program is a first-in-class GalNAc-siRNA, which improves liver function in patients with cirrhosis by promoting liver regeneration.
